• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CCL18:戈谢病患者中戈谢细胞负荷的尿液标志物。

CCL18: a urinary marker of Gaucher cell burden in Gaucher patients.

作者信息

Boot Rolf G, Verhoek Marri, Langeveld Mirjam, Renkema G Herma, Hollak Carla E M, Weening Jan J, Donker-Koopman Wilma E, Groener Johanna E, Aerts Johannes M F G

机构信息

Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

J Inherit Metab Dis. 2006 Aug;29(4):564-71. doi: 10.1007/s10545-006-0318-8. Epub 2006 May 30.

DOI:10.1007/s10545-006-0318-8
PMID:16736095
Abstract

Glucosylceramide-laden tissue macrophages in Gaucher patients secrete large quantities of chitotriosidase and CC chemokine ligand 18 (CCL18), resulting in markedly increased plasma levels. We have comparatively investigated the occurrence of both parameters in plasma and urine samples of Gaucher patients. Chitotriosidase was high in urine samples of some symptomatic patients, but elevations did not correlate with increased plasma concentrations. Urinary chitotriosidase was particularly high in a patient with severe kidney involvement and local storage cell infiltration. Urinary levels of CCL18 were also highly elevated in samples from Gaucher patients as compared to controls. The median value of the CCL18/creatinine ratio in urine samples of 31 Gaucher patients was 143.3 pg/micromol (range 32-551) and in those of 12 normal subjects was 4.1 pg/micromol (range 1.3-6.8). In sharp contrast to chitotriosidase, increases in the low-molecular-mass chemokine CCL18 in urine and plasma specimens of Gaucher patients correlated well. A correlation was also observed for reductions in urinary and plasma CCL18 following therapy. It is concluded that assessment of urinary CCL18 of Gaucher patients gives insight into the total body burden on Gaucher cells, whereas that of chitotriosidase does not. Urinary chitotriosidase appears rather to be a reflection of renal pathology.

摘要

戈谢病患者中富含葡糖神经酰胺的组织巨噬细胞会分泌大量的壳三糖苷酶和CC趋化因子配体18(CCL18),导致血浆水平显著升高。我们比较研究了戈谢病患者血浆和尿液样本中这两个参数的情况。一些有症状患者的尿液样本中壳三糖苷酶水平较高,但升高情况与血浆浓度增加无关。在一名有严重肾脏受累和局部贮积细胞浸润的患者中,尿壳三糖苷酶特别高。与对照组相比,戈谢病患者样本中CCL18的尿液水平也显著升高。31名戈谢病患者尿液样本中CCL18/肌酐比值的中位数为143.3 pg/微摩尔(范围32 - 551),12名正常受试者的该比值中位数为4.1 pg/微摩尔(范围1.3 - 6.8)。与壳三糖苷酶形成鲜明对比的是,戈谢病患者尿液和血浆样本中低分子量趋化因子CCL18的增加情况相关性良好。治疗后尿液和血浆中CCL18的降低情况也存在相关性。得出的结论是,评估戈谢病患者的尿液CCL18可深入了解戈谢细胞的全身负荷情况,而壳三糖苷酶则不能。尿壳三糖苷酶似乎更反映肾脏病理情况。

相似文献

1
CCL18: a urinary marker of Gaucher cell burden in Gaucher patients.CCL18:戈谢病患者中戈谢细胞负荷的尿液标志物。
J Inherit Metab Dis. 2006 Aug;29(4):564-71. doi: 10.1007/s10545-006-0318-8. Epub 2006 May 30.
2
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.戈谢病中趋化因子CCL18/PARC显著升高:一种评估治疗干预的新型替代标志物。
Blood. 2004 Jan 1;103(1):33-9. doi: 10.1182/blood-2003-05-1612. Epub 2003 Sep 11.
3
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis.血浆壳三糖苷酶和 CCL18 作为肉样瘤病中肉芽肿性巨噬细胞的替代标志物。
Clin Chim Acta. 2010 Jan;411(1-2):31-6. doi: 10.1016/j.cca.2009.09.034. Epub 2009 Oct 4.
4
Elevated plasma chemokine CCL18/PARC in beta-thalassemia.β地中海贫血患者血浆趋化因子CCL18/PARC水平升高。
Blood Cells Mol Dis. 2005 Nov-Dec;35(3):328-31. doi: 10.1016/j.bcmd.2005.07.006. Epub 2005 Aug 31.
5
Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases.戈谢病及其他溶酶体贮积病中生物标志物的鉴定与应用。
Acta Paediatr Suppl. 2005 Mar;94(447):43-6; discussion 37-8. doi: 10.1111/j.1651-2227.2005.tb02110.x.
6
Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data.血浆壳三糖苷酶活性与CCL18水平用于评估I型戈谢病严重程度:个体参与者数据的系统评价与荟萃分析方案
Syst Rev. 2017 Apr 20;6(1):87. doi: 10.1186/s13643-017-0483-x.
7
Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.使用同位素标准品对1型戈谢病患者血浆和尿液中的葡萄糖基神经酰胺进行质谱定量分析。
Blood Cells Mol Dis. 2015 Apr;54(4):307-14. doi: 10.1016/j.bcmd.2015.01.006. Epub 2015 Jan 17.
8
Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease.血浆壳三糖苷酶和CCL18:B型尼曼-匹克病的早期生化替代标志物。
J Inherit Metab Dis. 2005;28(1):13-20. doi: 10.1007/s10545-005-4416-9.
9
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.几丁质酶活性和 CCL18 浓度评估 I 型戈谢病严重程度的准确性。一项基于个体参与者数据的系统评价和荟萃分析。
Haematologica. 2021 Feb 1;106(2):437-445. doi: 10.3324/haematol.2019.236083.
10
CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency.CCL18作为戈谢病和伴有壳三糖苷酶缺乏症的尼曼-匹克病的替代标志物。
Blood Cells Mol Dis. 2010 Jan 15;44(1):38-40. doi: 10.1016/j.bcmd.2009.09.005. Epub 2009 Oct 9.

引用本文的文献

1
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.几丁质酶活性和 CCL18 浓度评估 I 型戈谢病严重程度的准确性。一项基于个体参与者数据的系统评价和荟萃分析。
Haematologica. 2021 Feb 1;106(2):437-445. doi: 10.3324/haematol.2019.236083.
2
Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models.1型戈谢病患者及小鼠模型中糖蛋白非转移性黑色素瘤蛋白B的升高。
FEBS Open Bio. 2016 Jul 30;6(9):902-13. doi: 10.1002/2211-5463.12078. eCollection 2016 Sep.
3

本文引用的文献

1
Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.戈谢病趋化因子和酶生物标志物的临床评估
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):259-67. doi: 10.1016/j.bcmd.2005.05.005.
2
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages.戈谢细胞表现出独特的巨噬细胞表型,类似于交替激活的巨噬细胞。
Am J Clin Pathol. 2004 Sep;122(3):359-69. doi: 10.1309/BG5V-A8JR-DQH1-M7HN.
3
Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.
Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease.
Gpnmb是尼曼-匹克C型病内脏病理的潜在标志物。
PLoS One. 2016 Jan 15;11(1):e0147208. doi: 10.1371/journal.pone.0147208. eCollection 2016.
4
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.用于治疗成年1型戈谢病患者的酒石酸 eliglustat
Drug Des Devel Ther. 2015 Aug 18;9:4639-47. doi: 10.2147/DDDT.S77760. eCollection 2015.
5
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.酸性鞘磷脂酶缺乏症患者中奥利普酶α成功进行患者内剂量递增。
Mol Genet Metab. 2015 Sep-Oct;116(1-2):88-97. doi: 10.1016/j.ymgme.2015.05.013. Epub 2015 May 30.
6
Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.溶酶体贮积症诊断中的生物标志物:蛋白质、脂质和抑制物。
J Inherit Metab Dis. 2011 Jun;34(3):605-19. doi: 10.1007/s10545-011-9308-6. Epub 2011 Mar 29.
7
Laboratory and genetic evaluation of Gaucher disease.戈谢病的实验室及基因评估
Wien Med Wochenschr. 2010 Dec;160(23-24):600-4. doi: 10.1007/s10354-010-0814-1. Epub 2010 Aug 16.
8
Optimal therapy in Gaucher disease.戈谢病的最佳治疗方法。
Ther Clin Risk Manag. 2010 Jul 21;6:315-23. doi: 10.2147/tcrm.s6955.
9
Human chitinases and chitinase-like proteins as indicators for inflammation and cancer.人类几丁质酶和几丁质酶样蛋白作为炎症和癌症的指标。
Biomark Insights. 2007 May 3;2:128-46.
10
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.非神经元型戈谢病的管理,特别涉及妊娠、脾切除术、双膦酸盐治疗、生物标志物的使用及骨病监测。
J Inherit Metab Dis. 2008 Jun;31(3):319-36. doi: 10.1007/s10545-008-0779-z. Epub 2008 May 23.
小儿非神经元型戈谢病:治疗与监测建议
Eur J Pediatr. 2004 Feb;163(2):67-75. doi: 10.1007/s00431-003-1363-z. Epub 2003 Dec 16.
4
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.亚氨基糖N-丁基脱氧野尻霉素(米格列醇)在I型(非神经病变型)戈谢病治疗中的作用:一份立场声明。
J Inherit Metab Dis. 2003;26(6):513-26. doi: 10.1023/a:1025902113005.
5
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.戈谢病中趋化因子CCL18/PARC显著升高:一种评估治疗干预的新型替代标志物。
Blood. 2004 Jan 1;103(1):33-9. doi: 10.1182/blood-2003-05-1612. Epub 2003 Sep 11.
6
Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase.壳三糖苷酶的转糖苷酶活性:针对人巨噬细胞几丁质酶的改良酶促测定法
J Biol Chem. 2003 Oct 17;278(42):40911-6. doi: 10.1074/jbc.M301804200. Epub 2003 Jul 30.
7
Future perspectives for glycolipid research in medicine.糖脂在医学研究中的未来展望。
Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):967-73. doi: 10.1098/rstb.2003.1270.
8
Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention.糖鞘脂贮积症的生物化学:对治疗干预的影响
Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):905-14. doi: 10.1098/rstb.2003.1273.
9
Clinically relevant therapeutic endpoints in type I Gaucher disease.I型戈谢病的临床相关治疗终点
J Inherit Metab Dis. 2001;24 Suppl 2:97-105; discussion 87-8. doi: 10.1023/a:1012492429191.
10
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.抑制底物合成作为糖脂溶酶体贮积病治疗策略。
J Inherit Metab Dis. 2001 Apr;24(2):275-90. doi: 10.1023/a:1010335505357.